<DOC>
	<DOC>NCT01435460</DOC>
	<brief_summary>This study is to evaluate the safety and efficacy of Alrex (LE ophthalmic suspension, 0.2%) versus Patanol (olopatadine hydrochloride ophthalmic solution, 0.1%) in the temporary relief of the signs and symptoms of Seasonal Allergic Conjunctivitis (SAC).</brief_summary>
	<brief_title>AlrexÂ® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Subjects who are diagnosed with acute SAC and experience at least grade 4 ocular itching and at least grade 2 bulbar conjunctival injection (redness) in each eye due to seasonal allergy at Visit 1. Subjects who have a known hypersensitivity to the study medications or their components or contraindications to ocular corticosteroids. Subjects who use any of the disallowed medications throughout the duration of the study and during the period indicated prior to Visit 1. Subjects who have intraocular pressure (IOP) greater than 21 mm Hg in either eye or any type of glaucoma. Subjects who have a history of any severe/serious ocular pathology or medical condition that could result in the subject's inability to complete the study or affect the subject's safety or trial parameters.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>ocular allergy</keyword>
</DOC>